Charting New Heights: TTM Technologies' Record-Breaking Financial Journey
Setting New Financial Benchmarks for Success
TTM Technologies reached an unprecedented milestone in the second quarter of 2026, recording $1 billion in revenue, a 37% increase year-over-year. This achievement marks the first time the company has surpassed this revenue threshold. Alongside this, non-GAAP earnings per diluted share surged by 71% to $0.99, exceeding previous guidance and setting a new quarterly record. The adjusted EBITDA margin also saw a healthy increase to 16.6%, reflecting favorable market conditions and efficient operational management.
Key Performance Indicators: A Deeper Dive into Growth Drivers
The company's strong performance was underpinned by robust sales across several critical segments. Aerospace and Defense sales reached $370 million, comprising 37% of total revenue, driven by defense budget tailwinds and new program bookings. Data Center and Networking sales soared to $400 million, or 40% of total revenue, experiencing a 91% year-over-year growth due to the escalating demands of artificial intelligence infrastructure. The Medical, Industrial, and Instrumentation segment also contributed significantly, accounting for 50% of second-quarter revenue and growing by 33%, primarily fueled by continuous glucose monitoring products. Despite a marginal decrease in Automotive sales (8% of revenue), the company's focus remains on high-value products within this sector.
Strategic Outlook and Future Projections
TTM Technologies maintains an optimistic outlook, projecting net sales for the third quarter of 2026 to be between $1.10 billion and $1.14 billion, with non-GAAP earnings per diluted share expected to range from $1.21 to $1.27. For the full year 2026, the company anticipates sales of approximately $4.4 billion and non-GAAP earnings approaching $5 per diluted share. These projections exclude any impact from pending acquisitions. Management is confident in achieving 15% to 20% organic revenue growth for 2027 and 2028, driven by continued strong demand in AI and defense markets.
Expanding Global Footprint and Technological Advancements
As part of its strategic growth, TTM is expanding its manufacturing capabilities and global presence. The company plans to acquire two European firms, Swiss Technology Group AG and ILFA GmbH, which will establish its first manufacturing footprint in Europe, focusing on medical and aerospace/defense markets. Furthermore, TTM is accelerating capital expenditures to support the volume production of N+M asymmetrical interconnect printed circuit boards, a critical technology for advanced data centers. The Syracuse facility is also ramping up for Ultra-HDI product manufacturing, with full capacity expected by 2028.
Leadership Perspectives on Market Dynamics and Innovation
Edwin Roks, President and CEO, emphasized the company's focus on designing and manufacturing complex advanced interconnect products, including RF modules and integrated mission systems. He highlighted the strategic alignment with the megatrends of artificial intelligence and defense as key drivers of performance. Daniel Boehle, Executive Vice President and CFO, detailed the financial results, noting improvements in gross margin and operating leverage due to disciplined expense management. Both leaders reiterated the company's commitment to innovation, customer engagement, and strategic acquisitions to enhance business and financial strength.
Operational Highlights and Industry Insights
The company's operational achievements include a total book-to-bill ratio of 1.49, with a strong aerospace and defense program backlog of $1.7 billion. The 90-day backlog increased by 81% year-over-year to $901 million. TTM's Qualified Aerospace and Defense Pipeline now stands at an all-time high of $7 billion, indicating significant future business potential. Management also addressed supply chain dynamics, noting a shift towards higher-end materials by Copper Clad Laminate (CCL) producers, which TTM is actively managing to ensure adequate supply for its customers.
Financial Health and Shareholder Value
TTM Technologies generated $96.4 million in cash flow from operating activities and $46.0 million in free cash flow in Q2 2026, demonstrating robust financial health. The company maintains a healthy net leverage ratio of 0.9x while continuing investments in global facilities. These strong financial indicators, combined with strategic growth initiatives, position TTM for sustained long-term value creation for its shareholders.
